HKSE - Delayed Quote HKD

Giant Biogene Holding Co., Ltd. (2367.HK)

84.900
+0.350
+(0.41%)
At close: May 16 at 4:08:18 PM GMT+8
Loading Chart for 2367.HK
  • Previous Close 84.550
  • Open 84.600
  • Bid 84.650 x --
  • Ask 84.700 x --
  • Day's Range 82.750 - 85.000
  • 52 Week Range 35.000 - 85.350
  • Volume 3,785,471
  • Avg. Volume 6,075,713
  • Market Cap (intraday) 86.906B
  • Beta (5Y Monthly) 0.84
  • PE Ratio (TTM) 38.07
  • EPS (TTM) 2.230
  • Earnings Date Mar 26, 2025
  • Forward Dividend & Yield 0.65 (0.76%)
  • Ex-Dividend Date Jun 17, 2025
  • 1y Target Est 86.12

Giant Biogene Holding Co., Ltd., an investment holding company, designs, develops, and manufactures skin treatment products with recombinant collagen in the People's Republic of China. It also develops and manufactures rare ginsenosides technology-based functional food products; and offers medical devices. The company offers its functional skincare products, medical dressings, and functional food products primarily under the Comfy, Collgene, Ke Yu, and SKIGIN brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.

www.xajuzi.com

1,758

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 2367.HK

View More

Performance Overview: 2367.HK

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2367.HK
69.12%
HANG SENG INDEX (^HSI)
16.38%

1-Year Return

2367.HK
62.00%
HANG SENG INDEX (^HSI)
20.48%

3-Year Return

2367.HK
226.54%
HANG SENG INDEX (^HSI)
17.02%

5-Year Return

2367.HK
226.54%
HANG SENG INDEX (^HSI)
1.90%

Compare To: 2367.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2367.HK

View More

Valuation Measures

As of 5/16/2025
  • Market Cap

    86.91B

  • Enterprise Value

    80.57B

  • Trailing P/E

    38.06

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.18

  • Price/Book (mrq)

    11.29

  • Enterprise Value/Revenue

    13.43

  • Enterprise Value/EBITDA

    29.67

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    37.23%

  • Return on Assets (ttm)

    21.92%

  • Return on Equity (ttm)

    35.88%

  • Revenue (ttm)

    5.54B

  • Net Income Avi to Common (ttm)

    2.06B

  • Diluted EPS (ttm)

    2.230

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.88B

  • Total Debt/Equity (mrq)

    0.09%

  • Levered Free Cash Flow (ttm)

    1.44B

Research Analysis: 2367.HK

View More

People Also Watch